logo-loader

Hikma Pharma moved to ‘Hold’ from ‘Add’ by Peel Hunt on valuation grounds, says forecast upgrades already priced in

Published: 10:13 12 Nov 2018 GMT

Pharmaceuticals
Hikma’s share price has risen around 61% since the start of the year

Hikma Pharmaceuticals PLC (LON:HIK) has been downgraded to ‘Hold’ from ‘Add’ by City broker Peel Hunt on valuation grounds, saying upgrades to earnings forecasts have already been factored into the share price.

In a note to clients, analysts at the broker said an upgrade to the FTSE 250 firm’s full-year guidance in a third-quarter trading update last Thursday had led them to upgrade their earnings per share (EPS) forecasts to 5%-21% for 2018-2022, about 8%-23% above consensus.

READ: Hikma and Vectura to develop generic version of GSK’s blockbuster Ellipta inhaler

However, despite the upgrades, the broker said the strong performance indicators were already factored into Hikma’s share price, which has risen around 61% since the start of the year.

As a result, analysts said a bounce in the market may deliver an upside, but outperformance “may be trickier” given the surge, although it upped its target price to 2,000p from 1,950p.

Peel Hunt added that there was still scope for Hikma’s shares to appreciate when sentiment recovered in the wider market.

In mid-morning trading Monday, Hikma shares were down 2.9% at 1,799.5p.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

5 minutes ago